Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer

Molecular Pharmaceutics

Volumn 11, Issue 8, 2014, Pages 2623-2630

  Ma, Yan ^b   Liu, Dan ^c   Wang, Dun ^c   Wang, Yongjun ^c   Fu, Qiang ^c   Fallon, John K ^a   Yang, Xinggang ^c   He, Zhonggui ^c   Liu, Feng ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

5 fluorouracil; codelivery; core matched nanoemulsions; multidrug resistance; paclitaxel

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALPHA TOCOPHEROL; BETA TUBULIN; FLUOROURACIL; MACROGOL DERIVATIVE; NANOPARTICLE; PACLITAXEL; POLY(ETHYLENE GLYCOL)SUCCINATE; PROTEIN P53; TOCOPHEROL; UNCLASSIFIED DRUG; ALPHA-TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; ANTINEOPLASTIC AGENT; EMULSION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CARCINOMA CELL LINE; CELL AGING; CELL CYCLE PROGRESSION; CELL DAMAGE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG SOLUBILITY; FEASIBILITY STUDY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HYDROPHILICITY; HYDROPHOBICITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MISMATCH REPAIR; MOUSE; MULTIDRUG RESISTANCE; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SENESCENCE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CANCER TRANSPLANTATION; CELL CYCLE; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; EMULSION; HUMAN; IC50; NANOMEDICINE; NUDE MOUSE; PROCEDURES; SKIN NEOPLASMS; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EMULSIONS; FEMALE; FLUOROURACIL; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INHIBITORY CONCENTRATION 50; MICE; MICE, NUDE; NANOMEDICINE; NEOPLASM TRANSPLANTATION; PACLITAXEL; POLYETHYLENE GLYCOLS; SKIN NEOPLASMS; VITAMIN E;

EID: 84905447356     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400778r     Document Type: Article

References (29)

1. Keith, C. T.; Borisy, A. A.; Stockwell, B. R. Multicomponent therapeutics for networked systems Nat. Rev. Drug Discovery 2005, 4, 71-78
2. Cascinu, S.; Ficarelli, R.; Safi, M. A.; Graziano, F.; Catalano, G.; Cellerino, R. A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer Eur. J. Cancer. 1997, 33, 1699-1702
3. Kim, Y. H.; Shin, S. W.; Kim, B. S.; Kim, J. H.; Kim, J. G.; Mok, Y. J.; Kim, C. S.; Rhyu, H. S.; Hyun, J. H.; Kim, J. S. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma Cancer 1999, 85, 295-301
4. Paul, D. M.; Garrett, A. M.; Meshad, M.; DeVore, R. D.; Porter, L. L.; Johnson, D. H. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience Semin. Oncol. 1996, 23, 48-52
5. Smorenburg, C. H.; Sparreboom, A.; Bontenbal, M.; Verweij, J. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations Eur. J. Cancer 2001, 37, 2310-2323
6. Kim, Y. J.; Bang, S.; Park, J. Y.; Park, S. W.; Chung, J. B.; Song, S. Y. Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer Cancer Chemother. Pharmacol. 2009, 63, 529-533
7. Eiseman, J. L.; Eddington, N. D.; Leslie, J.; MacAuley, C.; Sentz, D. L.; Zuhowski, M.; Kujawa, J. M.; Young, D.; Egorin, M. J. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice Cancer Chemother. Pharmacol. 1994, 34, 465-471
8. Li, Y.; Looney, G. A.; Kimler, B. F.; Hurwitz, A. Opiate effects on 5-fluorouracil disposition in mice Cancer Chemother. Pharmacol. 1997, 39, 273-277
9. Mayer, L. D.; Janoff, A. S. Optimizing combination chemotherapy by controlling drug ratios Mol. Interventions 2007, 7, 216-223
10. Date, A. A.; Desai, N.; Dixit, R.; Nagarsenker, M. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances Nanomedicine 2010, 5, 1595-1616
11. Dintaman, J. M.; Silverman, J. A. Inhibition of P-glycoprotein by d -alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) Pharm. Res. 1999, 16, 1550-1556
12. Zhang, Z.; Tan, S.; Feng, S. S. Vitamin E TPGS as a molecular biomaterial for drug delivery Biomaterials 2012, 33, 4889-4906
13. Collnot, E. M.; Baldes, C.; Schaefer, U. F.; Edgar, K. J.; Wempe, M. F.; Lehr, C. M. Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access Mol. Pharmaceutics 2010, 7, 642-651
14. Collnot, E. M.; Baldes, C.; Wempe, M. F.; Kappl, R.; Huttermann, J.; Hyatt, J. A.; Edqar, K. J.; Schaefer, U. F.; Lehr, C. M. Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity Mol. Pharmaceutics 2007, 4, 465-474
15. Tang, J. L.; Fu, Q.; Wang, Y. J.; Racette, K.; Wang, D.; Liu, F. Vitamin E reverses multidrug resistance in vitro and in vivo Cancer Lett. 2013, 336, 149-157
16. Singla, A. K.; Garg, A.; Aggarwal, D. Paclitaxel and its formulations Int. J. Pharm. 2002, 235, 179-192
17. Sahoo, S. K.; Labhasetwar, V. Nanotech approaches to drug delivery and imaging Drug Discovery Today 2003, 8, 1112-1120
18. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 2010, 70, 440-446
19. Elledge, S. J. Cell cycle checkpoints: preventing an identity crisis Science 1996, 274, 1664-1672
20. Horwitz, S. B. Taxol (paclitaxel): mechanisms of action Ann. Oncol. 1994, 5, S3-S6
21. Tokunaga, E.; Oda, S.; Fukushima, M.; Maehara, Y.; Sugimachi, K. Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines Eur. J. Cancer 2000, 36, 1998-2006
22. Jordan, A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle Med. Res. Rev. 1998, 18, 259-296
23. Wang, D.; Tang, J. L.; Wang, Y. J.; Ramishetti, S.; Fu, Q.; Racette, K.; Liu, F. Multifunctional nanoparticles based on a single-molecule modification for the treatment of drug-resistant cancer Mol. Pharmacol. 2013, 10, 1465-1469
24. Pietsch, E. C.; Sykes, S. M.; McMahon, S. B.; Murphy, M. E. The p53 family and programmed cell death Oncogene 2008, 27, 6507-6521
25. Sheikh, M. S.; Fornace, A. J., Jr. Role of p53 family members in apoptosis J. Cell Physiol. 2000, 182, 171-181
26. Stewart, N.; Hicks, G. G.; Paraskevas, F.; Mowat, M. Evidence for a second cell cycle block at G2/M by p53 Oncogene 1995, 10, 109-115
27. Lowe, S. W.; Ruley, H. E.; Jacks, T.; Housman, D. E. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 1993, 74, 957-967
28. Jokerst, J. V.; Lobovkina, T.; Zare, R. N.; Gambhir, S. S. Nanoparticle PEGylation for imaging and therapy Nanomedicine 2011, 6, 715-728
29. Li, S. D.; Huang, L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer Biochim. Biophys. Acta 2009, 1788, 2259-2266